BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1089 related articles for article (PubMed ID: 27208741)

  • 21. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 22. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
    Song Z; Liu T; Chen J; Ge C; Zhao F; Zhu M; Chen T; Cui Y; Tian H; Yao M; Li J; Li H
    Cancer Lett; 2019 Sep; 460():96-107. PubMed ID: 31247273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peroxiredoxin II Is Essential for Maintaining Stemness by Redox Regulation in Liver Cancer Cells.
    Kwon T; Bak Y; Park YH; Jang GB; Nam JS; Yoo JE; Park YN; Bak IS; Kim JM; Yoon DY; Yu DY
    Stem Cells; 2016 May; 34(5):1188-97. PubMed ID: 26866938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133
    Hemati H; Kaur J; Sobti RC; Trehanpati N
    Biochem Biophys Res Commun; 2020 May; 525(4):941-947. PubMed ID: 32173531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma.
    Zhang M; Zhang W; Wu Z; Liu S; Sun L; Zhong Y; Zhang X; Kong X; Qian P; Zhang H; Lobie PE; Zhu T
    Oncotarget; 2016 Jan; 7(3):3267-82. PubMed ID: 26675549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxytetracycline have the therapeutic efficiency in CD133
    Song Y; Kim IK; Choi I; Kim SH; Seo HR
    Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
    Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM
    Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E
    Cells; 2020 May; 9(5):. PubMed ID: 32408542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incomplete radiofrequency ablation promotes the development of CD133
    Yuan CW; Wang ZC; Liu K; Liu DJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):416-422. PubMed ID: 30262419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma.
    Fung SW; Cheung PF; Yip CW; Ng LW; Cheung TT; Chong CC; Lee C; Lai PB; Chan AW; Tsao GS; Wong CH; Chan SL; Lo KW; Cheung ST
    Cancer Lett; 2019 Aug; 457():98-109. PubMed ID: 31100412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
    Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
    Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
    Song Y; Jang J; Shin TH; Bae SM; Kim JS; Kim KM; Myung SJ; Choi EK; Seo HR
    J Exp Clin Cancer Res; 2017 Mar; 36(1):38. PubMed ID: 28253902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
    Liu YM; Li XF; Liu H; Wu XL
    Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
    Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
    Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer and Antiangiogenic Activities of Novel α-Mangostin Glycosides in Human Hepatocellular Carcinoma Cells via Downregulation of c-Met and HIF-1α.
    Kim SM; Han JM; Le TT; Sohng JK; Jung HJ
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32516967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aquaporin 3 maintains the stemness of CD133+ hepatocellular carcinoma cells by activating STAT3.
    Wang Y; Wu G; Fu X; Xu S; Wang T; Zhang Q; Yang Y
    Cell Death Dis; 2019 Jun; 10(6):465. PubMed ID: 31197130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
    Seto K; Sakabe T; Itaba N; Azumi J; Oka H; Morimoto M; Umekita Y; Shiota G
    Anticancer Res; 2017 Jul; 37(7):3569-3579. PubMed ID: 28668848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
    Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
    Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.
    Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.